TY - THES A1 - Nattmann, Anja Maria T1 - ADAM9 und CXCR4 – neue Angriffspunkte in der Pathogenese des Vestibularisschwannoms T1 - ADAM9 and CXCR4 – new targets in vestibular schwannoma pathogenesis N2 - Obwohl es sich bei Vestibularisschwannomen (VS) um benigne Tumoren handelt, können sie die Lebensqualität der betroffenen Patienten deutlich beeinträchtigen. Gerade bei Patienten, die an einer NF 2 leiden und sich daher wiederholt operativen Eingriffen unterziehen müssen, ist es notwendig, eine medikamentöse Therapiealternative anbieten zu können, die ohne die Notwendigkeit einer operativen Intervention auskommt und gleichzeitig schwerwiegenden Folgen der Tumorerkrankung – wie dem drohenden Hörverlust – Einhalt gebietet. Die vorliegende Arbeit hatte zum Ziel, sich dieser medikamentösen Therapiealternative einen Schritt anzunähern, indem molekulare Pathomechanismen, die dem VS zugrunde liegen könnten, untersucht wurden. Im Mittelpunkt standen der Chemokinrezeptor CXCR4, das Tumorsuppressorprotein Merlin und die Metalloprotease ADAM9. Für CXCR4 ließen sich keine Effekte in Bezug auf die Aktivierung der ERK- und AKT-Signalwege erkennen. Auch beeinflusste eine Merlinüberexpression in VS-Zellen die CXCR4- und ADAM9-Proteinexpression nicht. Für ADAM9 zeigte sich eine potenzielle Relevanz für die Pathogenese des VS: Wurde die ADAM9-Konzentration durch einen knock-down reduziert, hatte dies eine verminderte VS-Zellzahl zur Folge. Des Weiteren scheint Integrin α6 ein Substrat von ADAM9 zu sein, das möglicherweise in die Zytoskelettmodifikation durch ADAM9 involviert ist. Somit stellt die ADAM9-Inhibition einen interessanten Angriffspunkt für eine mögliche medikamentöse Behandlung von VS dar. Ferner wurden Cytokine gefunden, die bisher nicht in einen Zusammenhang mit dem VS gebracht worden waren. Vor allem die Bedeutung der Cytokine TIMP-2 und CXCL7 sollte für das VS näher untersucht werden. Somit konnte diese Arbeit weitere Aspekte aufdecken, die für die Pathogenese des VS relevant sein könnten und an die zukünftige Forschung anknüpfen sollte. N2 - Although they are benign tumors, vestibular schwannomas have the potential to noticeably impair the patients’ quality of life. Especially patients suffering from neurofibromatosis type 2 develop multiple schwannomas and therefore often require repeated surgery. Thus, a non-invasive and effective pharmacotherapy is urgently needed to prevent severe consequences of vestibular schwannoma such as hearing loss. The aim of this thesis was to investigate pathological mechanisms of vestibular schwannoma to identify potential druggable targets. Especially the chemokine receptor CXCR4, the tumor suppressor protein Merlin and the metalloproteinase ADAM9 were in the focus of interest. Neither inhibition, nor stimulation of CXCR4 affected the activity of ERK and AKT signaling pathways, respectively. Similarly, Merlin overexpression did not change CXCR4 or ADAM9 protein expression in vestibular schwannoma. However, ADAM9 appeared to be potentially important for the pathogenesis of vestibular schwannoma: An ADAM9 knock-down led to reduced vestibular schwannoma cell numbers. Moreover, integrin α6 appeared to be a substrate of ADAM9 and might be involved in its mediation of cytoskeleton alterations. Thus, pharmacological inhibition of ADAM9 could be a promising therapeutic strategy to target vestibular schwannoma. In addition, a cytokine screen revealed the tissue inhibitor of metalloproteinases 2 (TIMP-2) and the chemokine ligand CXCL7 as hitherto unknown factors with putative relevance for the vestibular schwannoma pathogenesis. To conclude, this thesis revealed new perspectives on pathological mechanisms of vestibular schwannoma which deserve further investigation. KW - Akustikustumor KW - Vestibularisschwannom KW - ADAM9 KW - CXCR4 KW - Merlin KW - vestibular schwannoma Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-278086 ER - TY - JOUR A1 - Nattmann, Anja A1 - Breun, Maria A1 - Monoranu, Camelia M. A1 - Matthies, Cordula A1 - Ernestus, Ralf-Ingo A1 - Löhr, Mario A1 - Hagemann, Carsten T1 - Analysis of ADAM9 regulation and function in vestibular schwannoma primary cells JF - BMC Research Notes N2 - Objective Recently, we described a disintegrin and metalloproteinase 9 (ADAM9) overexpression by Schwann cells of vestibular schwannoma (VS) and suggested that it might be a marker for VS tumor growth and invasiveness. This research note provides additional data utilizing a small cohort of VS primary cultures and tissue samples. We examined whether reconstitution of Merlin expression in VS cells regulates ADAM9 protein expression and performed lentiviral ADAM9 knock down to investigate possible effects on VS cells numbers. Moreover, the co-localization of ADAM9 and Integrins α6 and α2β1, respectively, was examined by immunofluorescence double staining. Results ADAM9 expression was not regulated by Merlin in VS. However, ADAM9 knock down led to 58% reduction in cell numbers in VS primary cell cultures (p < 0.0001). While ADAM9 and Integrin α2β1 were co-localized in only 22% (2 of 9) of VS, ADAM9 and Integrin α6 were co-localized in 91% (10 of 11) of VS. Therefore, we provide first observations on possible regulatory functions of ADAM9 expression in VS. KW - vestibular schwannoma KW - pathogenesis KW - ADAM9 KW - knock down KW - integrin KW - immunofuorescence double staining KW - Merlin KW - primary cell culture Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-231213 VL - 13 ER - TY - JOUR A1 - Matthies, Cordula A1 - Brill, Stefan A1 - Kaga, Kimitaka A1 - Morita, Akio A1 - Kumakawa, Kozo A1 - Skarzynski, Henryk A1 - Claassen, Andre A1 - Hui, Yau A1 - Chiong, Charlotte A1 - Müller, Joachim A1 - Behr, Robert T1 - Auditory Brainstem Implantation Improves Speech Recognition in Neurofibromatosis Type II Patients JF - ORL N2 - This prospective study aimed to determine speech understanding in neurofibromatosis type II (NF2) patients following implantation of a MED-EL COMBI 40+ auditory brainstem implant (ABI). Patients (n = 32) were enrolled postsurgically. Nonauditory side effects were evaluated at fitting and audiological performance was determined using the Sound Effects Recognition Test (SERT), Monosyllable-Trochee-Polysyllable (MTP) test and open-set sentence tests. Subjective benefits were determined by questionnaire. ABI activation was documented in 27 patients, 2 patients were too ill for testing and 3 patients were without any auditory perception. SERT and MTP outcomes under auditory-only conditions improved significantly between first fitting and 12-month follow-up. Open-set sentence recognition improved from 5% at first fitting to 37% after 12 months. The number of active electrodes had no significant effect on performance. All questionnaire respondents were ‘satisfied' to ‘very satisfied' with their ABI. An ABI is an effective treatment option in NF2 patients with the potential to provide open-set speech recognition and subjective benefits. To our knowledge, the data presented herein is exceptional in terms of the open-set speech perception achieved in NF2 patients. KW - acoustic neuroma KW - auditory brainstem implant KW - nonauditory side effects KW - open-set sentence recognition KW - subjective benefits KW - vestibular schwannoma Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196383 SN - 0301-1569 SN - 1423-0275 N1 - This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. VL - 75 IS - 5 ER - TY - THES A1 - Kahle, Philipp T1 - Resttumore bei der mikrochirurgischen Therapie von Vestibularschwannomen - funktionelle Ergebnisse und radiologisches Verhalten T1 - Residual tumor in vestibular schwannoma surgery - functional outcome and radiological behaviour N2 - Einleitung: Zwischen 1994-2003 wurden in Zusammenarbeit von HNO- und Neurochirurgie 615 Vestibularschwannome (Grad T3a-T4b) über den subokzipitalen Zugang operiert. In 89 Fällen (14%) konnte aus unterschiedlichen Gründen der Tumor nur inkomplett entfernt werden. Mittels neurologischer Untersuchung und MRT wurde postoperativ das funktionelle Ergebnis bzw. das Wachstumsverhalten des Resttumors untersucht. Außerdem wurden die Art des Resttumors und die Gründe für eine inkomplette Resektion analysiert. Material und Methoden: Alle Tumore wurden unter stetigem Neuromonitoring (AEP, Fazialis-EMG) operiert. Reichte der Tumor bis an die kaudalen Hirnnerven (IX, X, XI, XII) heran, wurden diese ebenfalls überwacht. In der postoperativen Kontrolle erfolgten eine neurologische Untersuchung und eine MRT. Die Ergebnisse wurden mit vorausgegangenen Untersuchungen verglichen, um das Wachstumsverhalten des Resttumors und das funktionelle Ergebnis zu beurteilen. Die Operationsberichte wurden nach den Gründen der inkompletten Tumorentfernung gesichtet. Ergebnisse: Starke Adhärenz des Tumorgewebes zu den Hirnnerven (VII, VIII, kaudale Gruppe) oder zum Hirnstamm, interfaszikuläre Tumornester, eine Gefährdung der Blutversorgung, spontane Entladungen im EMG oder eine reduzierte Ableitbarkeit der AEPs zwangen den Operateur, die Präparation abzubrechen. Die durchschnittliche Tumorgröße in den Fällen der inkompletten Resektion betrug 26,8 mm vs. 19,4 mm bei kompletter Tumorentfernung. Der zurückgelassene Tumorrest bestand in 86% aus einem Kapselanteil, einem Tumorrasen oder interfaszikulären Tumornestern. Grobe Tumorreste waren die Ausnahme. 12 Monate postoperativ wurde bei den Patienten mit kompletter Resektion in 88% eine gute bis sehr gute Funktionalität (House/Brackmann Grad I-II) des Gesichtsnervs beobachtet, bei inkompletter Tumorentfernung in 75%. 66% (n=59) der Resttumore zeigten keine Progredienz, 13% (n=12) eine Wachstumstendenz ohne klinische Symptomatik, 6% (n=5) mussten erneut operiert werden (15%/n=13 keine Kontrolle). Der durchschnittliche Nachbeobachtungszeitraum betrug 48,1 Monate (1-134). Zusammenfassung: Trotz Zurücklassens eines Tumorrestes kommt es nur selten zu einem erneuten Tumorwachstum. In noch weniger Fällen muss eine Rezidivoperation durchgeführt werden. Dies rechtfertigt eine subtotale Tumorresektion in den Fällen einer Hirnnervengefährdung. Verzichtet man auf eine komplette Resektion, lässt sich auch bei sehr großen Tumoren ein gutes bis sehr gutes funktionelles Ergebnis erzielen. N2 - Objective: 615 vestibular schwannomas from grade T3a -T4b were operated between 1994-2003 in a joint intervention by ENT- and neurosurgeons using the suboccipital approach. In 89 operations (14%) some residual tumour could not be removed for different reasons. Clinical and MRI follow-up investigated regrowth rate and functional outcome. Type of residual tumour and reasons for incomplete removal were analyzed. Methods: All tumours were removed under multimodal cranial nerve monitoring using AEP, trigeminal and facial EMG. The caudal cranial nerves were monitored if the tumour extended to the IX, X, XI, or XIIth nerve. Clinical investigation and serial MRI-scans were used to follow up patients. Serial clinical and radiological follow ups were used to investigate radiological behaviour of residual tumour and its clinical consequences. Operational reports were reviewed for reasons of subtotal removal. Results: Strong adherence to cranial nerves (acoustic, facial or caudal), interfascicular growth pattern, drop of EMG or spontaneous firing, reduction of AEP and strong adherence to the brain stem or its vascular supply forced the surgeons to terminate the procedure. Average tumour size in case of incomplete resection was 26.8 mm vs.19.4 mm in complete resection cases. 86% of residual tumours consisted of residual capsula, a thin tumour layer or interfascicular tumour nests. Tumour decompression or gross total removals were exceptions. After 12 months a good to excellent facial nerve function (House/Brackmann I-II) was achieved in complete resection cases in 88% vs. 75% in incomplete resection cases. 66% (59) of residual tumours were not progressive, 13% (12) had progressive growth without any clinical or operative consequence, 6% (5) had to be re-operated (15%/n=13 lost to follow-up). Mean follow-up of all patiens was 48.1 months (1-134). Conclusions: A low percentage of tumour progression and an even lower rate of re-operations seem to justify a nearly complete resection if the tumour growth pattern or electrophysiological warnings force the surgeons to terminate the procedure in order to preserve neural function and therefore quality of life. KW - Akustikustumor KW - Mikrochirurgie KW - NMR-Tomographie KW - Neurofibromatose KW - Nervus facialis KW - Facialisl�hmung KW - Nervus vestibulocochlearis KW - acoustic neuroma KW - vestibular schwannoma KW - neurofibromatosis KW - microsurgery KW - MRI KW - facial nerv Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-52066 ER - TY - JOUR A1 - Gugel, Isabel A1 - Grimm, Florian A1 - Hartjen, Philip A1 - Breun, Maria A1 - Zipfel, Julian A1 - Liebsch, Marina A1 - Löwenheim, Hubert A1 - Ernemann, Ulrike A1 - Kluwe, Lan A1 - Mautner, Victor-Felix A1 - Tatagiba, Marcos A1 - Schuhmann, Martin Ulrich T1 - Risk stratification for immediate postoperative hearing loss by preoperative BAER (brainstem auditory evoked response) and audiometry in NF2-associated vestibular schwannomas JF - Cancers N2 - Both brainstem auditory evoked potentials (BAEP) and audiometry play a crucial role in neuro-oncological treatment decisions in Neurofibromatosis Type 2 associated (NF2) vestibular schwannoma (VS) as hearing preservation is the major goal. In this study, we investigated the risk of immediate postoperative hearing deterioration (>15 dB and/or 15% loss in pure-tone average [PTA]/ speech discrimination score [SDS] in a cohort of 100 operated VS (ears) in 72 NF2 patients by retrospective analysis of pre- and postoperative hearing data (PTA, SDS, American Association of Otolaryngology–Head and Neck Surgery [AAO-HNS], and brainstem auditory evoked potential [BAEP] class) taking into account relevant influencing factors, particularly preoperative audiometry and BAEP status and the extent of resection. Immediately after surgery, the hearing was preserved in 73% of ears and approximately ~60% of ears kept their hearing classes. Preoperative BAEP (p = 0.015) and resection amount (p = 0.048) significantly influenced postoperative hearing outcome. The prediction model for postoperative hearing deterioration/loss between preoperative BAEP and AAO-HNS class showed increased risk by increasing BAEP class. Twenty-one tumors/ears were identified with large BAEP and AAO-HNS class discrepancies (≥2 points) and were associated with a high (48–100%) risk of deafness after surgery in ears with preoperative available hearing. Overall, the results were heterogeneous but the better both BAEP and audiometry class before surgery, the higher the chance of hearing maintenance afterwards. Large resection amounts (e.g., 100% risk in near-total resections) exhibit a significant (p < 0.05) higher risk compared to smaller amounts (e.g., 10/20% in laser-coagulated/partially resected tumors). Our results emphasized the indispensable role of both hearing monitoring in form of audiometry and neurophysiology (BAEP) in the pre-and perioperative monitoring of NF2-associated VS. Both BAEP and audiometry are good prognostic markers for the postoperative hearing outcome. The extent of resection should be strictly guided by and adjusted to the intraoperative neurophysiological monitoring. KW - hearing preservation KW - neurofibromatosis type 2 KW - vestibular schwannoma KW - audiometry KW - brainstem auditory evoked potentials Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234165 SN - 2072-6694 VL - 13 IS - 6 ER - TY - JOUR A1 - Breun, Maria A1 - Monoranu, Camelia M. A1 - Kessler, Almuth F. A1 - Matthies, Cordula A1 - Löhr, Mario A1 - Hagemann, Carsten A1 - Schirbel, Andreas A1 - Rowe, Steven P. A1 - Pomper, Martin G. A1 - Buck, Andreas K. A1 - Wester, Hans-Jürgen A1 - Ernestus, Ralf-Ingo A1 - Lapa, Constantin T1 - [\(^{68}\)Ga]-Pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas JF - Frontiers in Oncology N2 - We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [\(^{68}\)Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [\(^{68}\)Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [\(^{68}\)Ga]Pentixafor PET/CT was visually positive in all cases. SUV\(_{mean}\) and SUV\(_{max}\) were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR\(_{mean}\) and TBR\(_{max}\) were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [\(^{68}\)Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression. KW - vestibular schwannoma KW - CXCR4 KW - PET/CT KW - molecular imaging KW - Pentixafor Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201863 VL - 9 IS - 503 ER - TY - THES A1 - Becker, Eugen T1 - Einsatz des CO\(_2\)-Faserlasers in der mikrochirurgischen Therapie von Akustikusneurinomen über den transtemporalen Zugansweg T1 - Use of flexible CO\(_2\)laser fiber in microsurgery for vestibular schwannoma via the middle cranial fossa approach N2 - Das Ziel dieser Studie war die Analyse der Ergebnisse der mikrochirurgischen Therapie von Akustikusneurinomen (AN) über den transtemporalen Zugangsweg unter Einsatz eines flexiblen CO2-Faserlasers (Omniguide®). Zu diesem Zweck wurde eine prospektive nicht randomisierte klinische Studie durchgeführt. Bei 20 aufeinander folgenden Patienten, bei denen eine mikrochirurgische Exstirpation des Tumors über den transtemporalen Zugangsweg erfolgte, wurde die Tumorresektion mit Hilfe des flexiblen CO2-Lasers durchgeführt (Lasergruppe, LG). Als Vergleichsgruppe wurden 20 Patienten mit vergleichbarer Tumorgröße und gleichem präoperativen Hörvermögen aus einer Kohorte von 76 Patienten ausgewählt (matched pairs), die zu einem früheren Zeitpunkt vom selben Operateur ohne Zuhilfenahme des Lasers operiert worden waren (Kontrollgruppe, KG). In der frühen postoperativen Phase konnte bei jeweils sechs Patienten beider Gruppen eine Facialisschwäche nach House-Brackmann (HB) Grad 2-4 festgestellt werden. Nach drei Monaten zeigte sich lediglich bei einem Patienten der KG noch eine leichte Facialisschwäche (HB-Grad 2). Der Erhalt der Facialisfunktion (HB-Grad 1 und 2) lag bei beiden Gruppen bei 100 %. Der Hörerhalt (Gardner-Robertson-Klasse 1 und 2 prä- und postoperativ) lag in der LG bei 72 % und in der KG bei 82 % ohne statistisch signifikanten Unterschied. Die absolute Operationszeit (Schnitt-Naht-Zeit) betrug in der KG 157 min und in der LG 160 min. Die Präparationszeit des Tumors lag in der KG bei 23,2 min und bei der LG bei 36,1 min. Durch den Einsatz des CO2-Lasers konnte zwar keine Reduktion der Operationszeit erreicht werden, jedoch zeigten sich im Vergleich zur konventionellen Technik postoperativ die gleichen guten funktionellen Ergebnisse, so dass der CO2-Laser eine sinnvolle Ergänzung für spezielle Fälle sein kann (z.B. bei stark vaskularisierten Tumoren). N2 - The aim of this study was to analyze the results of microsurgery in vestibular schwannomas (VS) with assistance of a flexible CO(2) laser fiber (Omniguide(®)) using the middle cranial fossa (MCF) approach. For that purpose we performed a prospective non-randomized clinical trial. In 20 consecutive patients suffering from VS and elected for microsurgery via the MCF approach, tumor resection was performed with the aid of the flexible CO(2) laser ("laser group", LG). Twenty patients with similar tumor volume and pre-operative hearing status out of a cohort of 76 patients previously treated by the same surgeon without laser were used as comparison group ("conventional group", CG) (matched-pair-technique). Facial weakness (House-Brackmann (HB) 2-4) was seen in early postoperative (p.o.) days in six patients in each group and all recovered completely by 3 months p.o., except one patient with HB 2 in CG. Facial nerve preservation rate (HB 1 + 2) was 100% in both groups. Hearing preservation rate (Gardner/Robertson class 1 + 2 or AAO-HNS A + B, pre- and postoperatively) was 72% in LG and 82% in CG, without significant difference. Overall time from incision to skin suture was 157 min (SD 55.9) in CG and 160 min (SD 39.7) in LG. Tumor preparation time was 23.2 min (SD 19.7) in CG and 36.1 min (SD 33.8) in LG. The use of a handheld flexible CO(2) laser fiber in VS-microsurgery is safe and subjectively facilitates tumor resection especially in "difficult" (e.g., highly vascularized) tumors. However, in this limited prospective trial the excellent functional outcome following conventional microsurgery could not be further improved, nor the surgical time reduced by means of the non-contact laser-tool. Focusing the use of the flexible CO(2) laser on "difficult" tumors may lead to different results in future. KW - CO₂ laser fiber KW - Akustikusneurinom KW - vestibular schwannoma KW - middle cranial fossa approach KW - CO₂-Laser Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164866 ER -